当前位置: X-MOL 学术BMC Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
BMC Cancer ( IF 3.8 ) Pub Date : 2021-09-15 , DOI: 10.1186/s12885-021-08693-9
Thomas Powles 1 , Toni K Choueiri 2 , Robert J Motzer 3 , Eric Jonasch 4 , Sumanta Pal 5 , Nizar M Tannir 4 , Sabina Signoretti 6 , Rajesh Kaldate 7 , Christian Scheffold 7 , Evelyn Wang 7 , Dana T Aftab 7 , Bernard Escudier 8 , Daniel J George 9
Affiliation  

Correction to: BMC Cancer 21, 904 (2021)

https://doi.org/10.1186/s12885-021-08630-w

Following publication of the original article [1], it was noticed that uncorrected page proofs were mistakenly published. The publishers apologise for this error. The original article [1] has been corrected.

Below is a table of corrections which have been implemented in the original article.

Section Originally published text Corrected text
Article note Rajesh Kaldate7 & Evelyn Wang7 Rajesh Kaldate7† & Evelyn Wang7†
Affiliation at the time of the study.
Abstract Trial registration: ClinicalTrials.gov NCT01865747 (registered on 05/31/2013). Trial registration: ClinicalTrials.gov NCT01865747 (registered on 05/31/2013). https://clinicaltrials.gov/ct2/show/NCT01865747
Table 1 note Plasma biomarker baseline and fold change data were available for 316 and 304 patients in the cabozantinib arm and 305 and 280 patients in the everolimus
arm, respectively, with the exception of for IL-8 in the everolimus arm, for which 304 and 279 patients had available data, respectively
Plasma biomarker baseline and fold change data were available for 316 and 304 patients in the cabozantinib arm and 305 and 280 patients in the everolimus arm, respectively, with the exception of IL-8 in the everolimus arm, for which 304 and 279 patients had available data, respectively
Figure 1 Footnote is missing High levels and low levels are defined by ≥median and < median, respectively.
NR, not reached.
Row 2 1.32 (0.95–1.83) 1.32 (0.95, 1.83)
Row 6 ΔIL8 ΔIL-8
Table 6
Row 11
IL8 IL-8
Table 6
Row 12
0.97 (0.87–1.07) 0.97 (0.87, 1.07)
Table 6
Row 16
ΔIL8 ΔIL-8
Table 6
Row 18
IL8 IL-8
Table 6
Row 21
IL8 / 1.35 (0.95–1.9) IL-8 / 1.35 (0.95, 1.9)
Table 6 note Biomarkers were included in the multivariable analysis if p < 0.10 in the univariate analyses. Hazard ratios are for high versus low biomarker levels. Δ Indicates the covariate is change in the biomarker at week 4; all other covariates are baseline biomarkers dichotomized at the median * p < 0.05 for the analysis Biomarkers were included in the multivariable analysis if p < 0.10 in the univariate analyses. Hazard ratios are for high versus low biomarker levels.
Δ indicates the covariate is change in the biomarker at week 4; all other covariates are baseline biomarkers dichotomized at the median * p < 0.05 for the analysis
Competing interests Dr. Powles has received honoraria from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has a consulting or advisory role with Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has received research funding from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and has received travel/accommodation/other expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche. Dr. Powles has received honoraria from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has a consulting or advisory role with Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has received research funding from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and has received travel/accommodation/other expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche.
Competing interests Dr. Wang is employed by Exelixis; and has stock/ownership interests with Exelixis. Dr. Wang is a former employee of Exelixis; has stock/ownership interests with Exelixis.
Additional file 1 ‘Track changed’ version was published Clean version is published this correction article and the original article has been udpated
  1. 1.

    Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, et al. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021;21(1):904. https://doi.org/10.1186/s12885-021-08630-w.

    Article Google Scholar

Download references

Affiliations

  1. Barts Cancer Institute, Queen Mary University of London, London, UK

    Thomas Powles

  2. Dana-Farber Cancer Center, Boston, MA, USA

    Toni K. Choueiri

  3. Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Robert J. Motzer

  4. University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Eric Jonasch & Nizar M. Tannir

  5. City of Hope National Medical Center, Duarte, CA, USA

    Sumanta Pal

  6. Brigham and Women’s Hospital, Boston, MA, USA

    Sabina Signoretti

  7. Exelixis, Inc, Alameda, CA, USA

    Rajesh Kaldate, Christian Scheffold, Evelyn Wang & Dana T. Aftab

  8. Gustave-Roussy, Villejuif, France

    Bernard Escudier

  9. Duke Cancer Institute, Durham, NC, USA

    Daniel J. George

Authors
  1. Thomas PowlesView author publications

    You can also search for this author in PubMed Google Scholar

  2. Toni K. ChoueiriView author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert J. MotzerView author publications

    You can also search for this author in PubMed Google Scholar

  4. Eric JonaschView author publications

    You can also search for this author in PubMed Google Scholar

  5. Sumanta PalView author publications

    You can also search for this author in PubMed Google Scholar

  6. Nizar M. TannirView author publications

    You can also search for this author in PubMed Google Scholar

  7. Sabina SignorettiView author publications

    You can also search for this author in PubMed Google Scholar

  8. Rajesh KaldateView author publications

    You can also search for this author in PubMed Google Scholar

  9. Christian ScheffoldView author publications

    You can also search for this author in PubMed Google Scholar

  10. Evelyn WangView author publications

    You can also search for this author in PubMed Google Scholar

  11. Dana T. AftabView author publications

    You can also search for this author in PubMed Google Scholar

  12. Bernard EscudierView author publications

    You can also search for this author in PubMed Google Scholar

  13. Daniel J. GeorgeView author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Powles.

†Rajesh Kaldate and Evelyn Wang's affiliation at the time of the study.

Additional file 1.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

Verify currency and authenticity via CrossMark

Cite this article

Powles, T., Choueiri, T.K., Motzer, R.J. et al. Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer 21, 1023 (2021). https://doi.org/10.1186/s12885-021-08693-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12885-021-08693-9

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative



中文翻译:

更正:METEOR 中基于血浆生物标志物的结果,卡博替尼对比依维莫司治疗晚期肾细胞癌的随机 3 期试验

更正:BMC Cancer 21, 904 (2021)

https://doi.org/10.1186/s12885-021-08630-w

在原始文章 [1] 发表后,人们注意到未更正的页面校样被错误地发表。出版商为此错误道歉。原文[1]已更正。

以下是原始文章中已实施的更正表。

部分 最初发表的文字 更正的文本
文章说明 Rajesh Kaldate 7 & Evelyn Wang 7 Rajesh Kaldate 7†和 Evelyn Wang 7†
研究时的隶属关系。
抽象的 试验注册:ClinicalTrials.gov NCT01865747(于 2013 年 5 月 31 日注册)。 试验注册:ClinicalTrials.gov NCT01865747(于 2013 年 5 月 31 日注册)。https://clinicaltrials.gov/ct2/show/NCT01865747
表 1 注 血浆生物标志物基线和倍数变化数据分别适用于卡博替尼组的 316 和 304 名患者以及依维莫司
组的305 和 280 名患者,但依维莫司组的 IL-8 除外,其中 304 和 279 名患者有可用数据分别
血浆生物标志物基线和倍数变化数据分别适用于卡博替尼组的 316 和 304 名患者以及依维莫司组的 305 和 280 名患者,但依维莫司组的 IL-8 除外,其中 304 和 279 名患者可用数据分别
图1 脚注丢失 高水平和低水平分别由≥中值和<中值定义。
NR,未达到。
第 2 行 1.32 (0.95–1.83) 1.32 (0.95, 1.83)
第 6 行 ΔIL8 ΔIL-8
表 6
第 11 行
IL8 IL-8
表 6
第 12 行
0.97 (0.87–1.07) 0.97 (0.87, 1.07)
表 6
第 16 行
ΔIL8 ΔIL-8
表 6
第 18 行
IL8 IL-8
表 6
第 21 行
IL8 / 1.35 (0.95–1.9) IL-8 / 1.35 (0.95, 1.9)
表 6 注 如果 在单变量分析中p < 0.10,则生物标志物被包括在多变量分析中。危险比针对高与低生物标志物水平。Δ 表示协变量是第 4 周生物标志物的变化;所有其他协变量是基线生物标志物,在中位数 * p  < 0.05 进行分析如果 在单变量分析中p < 0.10,则生物标志物被包括在多变量分析中。危险比针对高与低生物标志物水平。
Δ 表示协变量是第 4 周生物标志物的变化;所有其他协变量是基线生物标志物,在中位数 * p  < 0.05 进行分析
利益争夺 Powles 博士曾从安斯泰来制药、阿斯利康、百时美施贵宝、卫材、Exelixis、Incyte、Ipsen、强生、默克、默克、默克雪兰诺、默沙东、诺华、辉瑞、罗氏和西雅图遗传学获得酬金;在 Astellas Pharma、AstraZeneca、Bristol-Myers Squibb、Eisai、Exelixis、Incyte、Ipsen、Johnson & Johnson、Merck、Merck Serono、MSD、Novartis、Pfizer、Roche 和 Seattle Genetics 担任咨询或顾问角色;已获得安斯泰来制药、阿斯利康、百时美施贵宝、卫材、Exelixis、易普生、强生、默克、默克雪兰诺、默克、诺华、辉瑞、罗氏和西雅图遗传学的研究资助;并已收到阿斯利康、易普生、默沙东、辉瑞和罗氏的差旅/住宿/其他费用。Powles 博士曾从安斯泰来制药、阿斯利康、百时美施贵宝、卫材、Exelixis、Incyte、Ipsen、强生、默克、默克雪兰诺、默沙东、诺华、辉瑞、罗氏和西雅图遗传学获得酬金;在 Astellas Pharma、AstraZeneca、Bristol-Myers Squibb、Eisai、Exelixis、Incyte、Ipsen、Johnson & Johnson、Merck、Merck Serono、MSD、Novartis、Pfizer、Roche 和 Seattle Genetics 担任咨询或顾问角色;已获得安斯泰来制药、阿斯利康、百时美施贵宝、卫材、Exelixis、易普生、强生、默克、默克雪兰诺、默克、诺华、辉瑞、罗氏和西雅图遗传学的研究资助;并已收到阿斯利康、易普生、默沙东、辉瑞和罗氏的差旅/住宿/其他费用。
利益争夺 王博士受雇于 Exelixis;并拥有 Exelixis 的股票/所有权权益。王博士是 Exelixis 的前雇员;拥有 Exelixis 的股票/所有权权益。
附加文件 1 发布了“轨道更改”版本 这篇更正文章已发布干净版,原文章已更新
  1. 1.

    Powles T、Choueiri TK、Motzer RJ、Jonasch E、Pal S、Tannir NM 等。基于 METEOR 中血浆生物标志物的结果,卡博替尼与依维莫司在晚期肾细胞癌中的随机 3 期试验。BMC 癌症。2021;21(1):904。https://doi.org/10.1186/s12885-021-08630-w。

    文章 谷歌学术

下载参考

隶属关系

  1. 英国伦敦玛丽女王大学 Barts 癌症研究所

    托马斯·鲍尔斯

  2. Dana-Farber 癌症中心,波士顿,马萨诸塞州,美国

    Toni K. Choueiri

  3. 美国纽约州纽约市纪念斯隆凯特琳癌症中心

    罗伯特·J·莫策

  4. 德克萨斯大学 MD 安德森癌症中心,美国德克萨斯州休斯顿

    埃里克·乔纳什 (Eric Jonasch) 和尼扎尔·M·坦尼尔 (Nizar M. Tanir)

  5. 美国加利福尼亚州杜阿尔特市希望之城国家医疗中心

    苏曼塔·帕尔

  6. 美国马萨诸塞州波士顿布莱根妇女医院

    萨宾娜·西诺雷蒂

  7. Exelixis, Inc, 美国加利福尼亚州阿拉米达

    Rajesh Kaldate、Christian Scheffold、Evelyn Wang 和 Dana T. Aftab

  8. Gustave-Roussy, 维勒瑞夫, 法国

    伯纳德·埃斯库迪埃

  9. 美国北卡罗来纳州达勒姆杜克癌症研究所

    丹尼尔·J·乔治

作者
  1. Thomas Powles查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

  2. Toni K. Choueiri查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

  3. Robert J. Motzer查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

  4. Eric Jonasch查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

  5. Sumanta Pal查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

  6. Nizar M. Tanir查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

  7. Sabina Signoretti查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

  8. Rajesh Kaldate查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

  9. Christian Scheffold查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

  10. Evelyn Wang查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

  11. Dana T. Aftab查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

  12. Bernard Escudier查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

  13. Daniel J. George查看作者出版物

    您也可以在PubMed Google Scholar搜索此作者 

通讯作者

与托马斯·鲍尔斯的通信。

†Rajesh Kaldate 和 Evelyn Wang 在研究时的隶属关系。

附加文件 1.

开放获取本文根据知识共享署名 4.0 国际许可协议获得许可,该许可允许以任何媒体或格式使用、共享、改编、分发和复制,只要您适当注明原作者和来源,提供链接到知识共享许可,并指出是否进行了更改。本文中的图像或其他第三方材料包含在文章的知识共享许可中,除非在材料的信用额度中另有说明。如果文章的知识共享许可中未包含材料,并且您的预期用途未得到法律法规的允许或超出允许的用途,则您需要直接从版权所有者处获得许可。要查看此许可证的副本,请访问 http://creativecommons.org/licenses/by/4.0/。

重印和许可

通过 CrossMark 验证货币和真实性

引用这篇文章

Powles, T., Choueiri, TK, Motzer, RJ等。更正:基于 METEOR 中血浆生物标志物的结果,卡博替尼与依维莫司在晚期肾细胞癌中的随机 3 期试验。BMC 癌症 21, 1023 (2021)。https://doi.org/10.1186/s12885-021-08693-9

下载引文

  • 发表

  • DOI : https://doi.org/10.1186/s12885-021-08693-9

分享此文章

您与之共享以下链接的任何人都可以阅读此内容:

抱歉,本文目前没有可共享的链接。

由 Springer Nature SharedIt 内容共享计划提供

更新日期:2021-09-15
down
wechat
bug